Contact Us

08 8294 8664



Online Enquiry

* Required fields

The application of rTMS in Parkinson's disease

Posted By AIMedical International  
09:00 AM

We would like to cordially invite you to join our free webinar organised on Tuesday the 25th of May, 2021 (4PM - 5PM CEST) about the application of rTMS in Parkinson's disease. We've invited Professor dr. Teus van Laar and Emile D'Angremont of the University Medical Centre Groningen, The Netherlands (UMCG). More information about this webinar can be found below. We hope to see you there!

In recent years, innovative therapies such as repetitive transcranial magnetic stimulation (rTMS) have been applied to improve the quality of life of Parkinson’s disease patients. Additionally, diagnostic properties of TMS are being used to study Parkinson’s disease. Lefaucheur et al., (2020) reported probable efficacy (level B evidence) of high-frequency rTMS over the M1 and left DLPFC for the treatment of motor symptoms and depressive feelings in Parkinson's disease.

During this webinar we cover the latest advancements regarding the application of (r)TMS in treatment and diagnosis of Parkinson’s disease. The symptoms of Parkinson’s disease will be discussed as well as rTMS treatment protocols. Furthermore, the latest scientific findings regarding TMS and Parkinson’s disease will be covered.


Prof. dr. Teus van Laar

University Medical Center Groningen

Teus van Laar is a clinical neurologist by training, with special expertise in movement disorders, especially in Parkinson’s disease, and the effect of pharmacological interventions on this disease. He works at the University of Groningen, The Netherlands and has been the Medical Director of the Parkinson Expertice Center in Groningen since 2016.

Emile D'Angremont 

University Medical Centre Groningen

Emile D'Angremont is a technical physician who tries to bridge the gap between modern technology and daily clinical practice. During his research as a PhD-candidate, he focusses on the prediction of how patients with Parkinson's disease with cognitive decline or visual hallucinations respond to treatment with cholinesterase inhibitors. For this goal he uses PET and TMS (short-latency afferent inhibition).

Register here


More information regarding the webinar can be found on our website. The webinar will take place using the Zoom platform. You can register here using our online form from the Zoom platform. A few days before the webinar, you will receive the Zoom link to participate by email. Participation is free for everyone.